Skip To Main Content
Campus
  • Utbildning
Campus
  • Utbildning
View Full Results

InRange publication

InRange diabetes type 1

CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial

Tadej Battelino MD, PhD,Thomas Danne MD,Steve V Edelman MD,Pratik Choudhary MD,Eric Renard MD,Jukka Westerbacka MD, PhD,Bhaswati Mukherjee MD,Valerie Pilorget MD,Mathieu Coudert MSc,Richard M Bergenstal MD

Diabetes Obes Metab. 2022; 1- 11. doi:10.1111/dom.14898

Read the Complete Publication Here

See the result of the InRange study here

Learn more about TiR, the study
design and result of InRange

Read More

Read the Complete Publication Here
Relaterade Artiklar
Detectability of Autoimmune Type 1 Diabetes

Detectability of Autoimmune Type 1 Diabetes

Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.2

Läs mer
Infographic: Impact of Type 1 Diabetes Diagnosis

Infographic: Impact of Type 1 Diabetes Diagnosis

This infographic summarizes survey data* about the impact that families across the Nordic countries have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).

Läs mer
Time to Rethink T1D?

Time to Rethink T1D?

Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.

Läs mer